MedPath

Ibuprofen Versus Ibuprofen Plus Caffeine in the Treatment of Migraine.

Phase 3
Withdrawn
Conditions
Pain
Interventions
Registration Number
NCT01426971
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

- To compare the treatment groups in the reduction of pain score by at least 30 mm on a visual pain scale (VAS) at 60 minutes after study medication intake, compared to the baseline score (obtained before the study medication intake).

Secondary Objectives:

* To assess the proportion of patients with more than 50% pain relief, according to the VAS score at 45 minutes after study medication intake compared to baseline

* Determine the following aspects in the timing of study medication intake:

* Time to the first perception of pain relief

* Time to onset of meaningful pain relief

* Reduction of pain at 15, 30, 45, 60, 120 and 240 minutes after study medication intake, to be evaluated as the difference between the scores on VAS in each period and baseline

* To assess the pain according to the five items of Headache Relief Rating - HRR (0: strong worsening 1: slight worsening 2: no change 3: slight improvement 4: strong improvement) at 15, 30, 45 and 60 minutes after study medication intake, according to the diaries completed by the patients

* To check the proportion of the patients requiring the third tablet of study medication within 24 hours of starting the study treatment and when it occurred

* To check the timing and frequency of rescue medication intake, as well as the proportion of patients who used these medications within 24 hours of starting the treatment

* Safety assessment.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ibuprofen+caffeineIBUPROFEN + CAFFEINE2 capsules
IbuprofenIBUPROFEN2 capsules
Primary Outcome Measures
NameTimeMethod
Number of patients with reduction of at least 30mm in the visual scale (VAS) of painfrom baseline to 60 minutes
Secondary Outcome Measures
NameTimeMethod
Number of patients with more than 50% of pain reductionup to 45 minutes
Median time of the first perception of pain relief since study medication intake4 hours
Median time to onset of significant pain relief compared to the time of study medication intake4 hours
Headache Relief Rating score (HRR)up to 60 mins
Mean of VAS difference between each time after medication intake and the baseline.15, 30, 45, 60, 120 and 240 minutes post dose
Number of patients who used the third tablet of study medicationup to 24 hours
Number of patients requiring rescue medicationup to 24 hours
© Copyright 2025. All Rights Reserved by MedPath